Witnessing the stock’s movement on the chart, on Wednesday, TG Therapeutics Inc (NASDAQ: TGTX) had a quiet start as it plunged -0.28% to $24.50, before settling in for the price of $24.57 at the close. Taking a more long-term approach, TGTX posted a 52-week range of $6.46-$26.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 2506.46%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -41.65%. This publicly-traded company’s shares outstanding now amounts to $151.42 million, simultaneously with a float of $137.98 million. The organization now has a market capitalization sitting at $3.79 billion. At the time of writing, stock’s 50-day Moving Average stood at $22.97, while the 200-day Moving Average is $18.23.
TG Therapeutics Inc (TGTX) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. TG Therapeutics Inc’s current insider ownership accounts for 10.88%, in contrast to 59.32% institutional ownership. According to the most recent insider trade that took place on Jun 20 ’24, this organization’s Director sold 16,348 shares at the rate of 16.87, making the entire transaction reach 275,791 in total value, affecting insider ownership by 105,195. Preceding that transaction, on Jun 17 ’24, Company’s Director sold 9,585 for 16.39, making the whole transaction’s value amount to 157,098. This particular insider is now the holder of 99,293 in total.
TG Therapeutics Inc (TGTX) Earnings and Revenue Records
TG Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -41.65% and is forecasted to reach 0.74 in the upcoming year.
TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators
Let’s observe the current performance indicators for TG Therapeutics Inc (TGTX). It’s Quick Ratio in the last reported quarter now stands at 2.83. The Stock has managed to achieve an average true range (ATR) of 1.12. Alongside those numbers, its PE Ratio stands at $40.83, and its Beta score is 2.20. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 10.94. Similarly, its price to free cash flow for trailing twelve months is now 55.93.
In the same vein, TGTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.60, a figure that is expected to reach 0.02 in the next quarter, and analysts are predicting that it will be 0.74 at the market close of one year from today.
Technical Analysis of TG Therapeutics Inc (TGTX)
Going through the that latest performance of [TG Therapeutics Inc, TGTX]. Its last 5-days volume of 2.36 million was inferior to the volume of 3.68 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 95.26% While, its Average True Range was 1.09.
Raw Stochastic average of TG Therapeutics Inc (TGTX) in the period of the previous 100 days is set at 83.02%, which indicates a major fall in contrast to 90.27% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 43.59% that was lower than 56.98% volatility it exhibited in the past 100-days period.
